there will be continued interest in gene therapy: biotech analyst
Published 5 years ago • 1K plays • Length 3:23Download video MP4
Download video MP3
Similar videos
-
4:29
elevatebio ceo on disruptive potential for gene and cell therapies
-
6:44
spark therapeutics ceo on breakthroughs in gene therapy
-
6:26
sangamo therapeutics ceo: alzheimer's and parkinson's gene therapies | mad money | cnbc
-
12:21
breakthrough economy: cell and gene therapy innovations
-
3:02
uniqure ceo discusses company's positive data in hemophilia gene therapy treatment
-
2:41
biomarin ceo: study results for hemophilia gene therapy are as 'good as we could hope'
-
2:51
how this $1.8 million drug is trying to disrupt the drug pricing system
-
1:12
buying biotech in 2018: here's what to watch | cnbc
-
4:05
gene therapy basics (2022 update)
-
2:47
novartis to release new gene therapy drug that could cost $2 million
-
4:38
this biotech company is trying to stop or reverse age-related diseases
-
30:04
finding a "killer application" for novel biotech: avexis case study
-
3:03
new sickle cell gene therapies are a breakthrough, but prices are still too high
-
5:04
the bridge to accelerating gene therapies: the bespoke gene therapy consortium
-
4:25
bluebird ceo defends $1.8 million price tag for gene therapy drug
-
30:59
voyager research update: dr elisabeth fine
-
35:22
a dilemma in als, the first mash drug, & why gene therapy is hard
-
5:19
biomarin pharmaceutical ceo: treating hemophilia | mad money | cnbc
-
2:35
this company raised $100 million to bring gene therapy to the masses